As the global pharmaceutical landscape accelerates its shift toward intelligent and multifunctional drug delivery systems, Litchlab is strengthening its microsphere-based delivery platform to meet the growing demand for controlled-release, long-acting, and tissue-targeted therapies. With robust R&D, scalable manufacturing, and regulatory know-how, Litchlab is enabling novel delivery solutions across a wide spectrum of molecules—including small molecules, peptides, proteins, and nucleic acids—for both early-stage development and clinical translation.
Litchlab’s microsphere systems are built on a foundation of biodegradable polymers (e.g., PLGA, PLA, PCL) and natural biomaterials (e.g., gelatin, chitosan, alginate), offering customizable design options to enable diverse release kinetics and site-specific delivery. Key capabilities include:
Controlled particle size (1–200 μm) adaptable to injectable, implantable, or topical use
High encapsulation efficiency & drug stability for sensitive biologics and hydrophobic molecules
Tailored release profiles ranging from daily to monthly controlled release
Stimuli-responsive formulations (pH-sensitive, temperature-sensitive, enzyme-degradable)
Multi-compartment & dual-drug systems for combination therapies or resistance control
Flexible scale-up capabilities using emulsification, spray drying, solvent evaporation, and fluidized bed processing
Litchlab supports all stages of development—from proof-of-concept to clinical supply—with a full suite of analytical characterization tools (SEM, size distribution, release kinetics, in vitro/in vivo correlation) to ensure data-rich, reproducible delivery system design.
According to recent market projections, the global microsphere drug delivery market is expected to exceed $12 billion by 2030, with major growth driven by long-acting injectables (LAIs), vaccine adjuvant systems, targeted oncology treatments, and site-specific delivery for ophthalmic and orthopedic indications.
Litchlab is strategically positioned to address these key trends:
Integration with novel therapeutics: Enhancing CAR-T, gene therapy, and RNA-based drugs through programmable release
Organ- and tissue-specific delivery: Using peptide or antibody surface modification to target lungs, joints, tumors, or liver
Multi-modal delivery systems: Co-delivery of small molecules with nucleic acids or proteins for synergistic therapy
Personalized dosing design: Customizing microsphere systems based on patient profiles and disease kinetics
Litchlab’s microsphere systems are applicable to a wide range of therapeutic areas:
| Disease Area | Applications |
|---|---|
| Oncology | Localized release of chemotherapeutics and immuno-oncology agents |
| Diabetes/Metabolic | Weekly/monthly depot formulations of peptide-based drugs (e.g., GLP-1 agonists) |
| Neurology/Psychiatry | Long-acting antipsychotic and antidepressant injectables |
| Vaccines | Controlled antigen/adjuvant co-delivery for enhanced immunogenicity |
| Ophthalmology/Orthopedics | Injectable/implantable depot formulations for chronic site-specific conditions |
Litchlab has already supported multiple preclinical and IND-enabling microsphere projects with integrated services ranging from formulation design, pharmacokinetics studies, stability testing, to CMC documentation preparation. The company is currently expanding its GMP microsphere manufacturing facilities to support late-stage clinical and commercial batches.
Litchlab collaborates globally with biopharma companies, academic labs, and vaccine developers through:
US/EU/China regulatory alignment with deep understanding of FDA, EMA, and NMPA requirements for complex injectables
Rapid prototyping with formulation turnaround times under 4 weeks
End-to-end CDMO services across APIs, delivery systems, and clinical packaging
Litchlab is a contract development and manufacturing organization (CDMO) focused on advanced drug delivery technologies. With platforms spanning liposomes, lipid nanoparticles (LNPs), microspheres, hydrogels, PEGylation, antibody-drug conjugates (ADC/RDC), protein nanoparticles, and nucleic acid carriers, Litchlab serves biopharma clients across oncology, infectious disease, rare disease, and immunotherapy fields. Our mission is to create a global ecosystem for high-efficiency, targeted, and safe therapeutic delivery.
Contact: RD2@litchlab.com
Learn more: www.litchlab.com
